€30m call launched for neurodegenerative-focussed precision medicine

Exscientia & GT Apeiron enter AI drug discovery partnership
Credit: Shutterstock.com/ Gorodenkoff

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has launched a €30 million call for multinational research on personalised medicines aimed at neurodegenerative diseases.

Debilitating and still largely untreatable, neurodegenerative diseases are characterised by a large variability in their origins, mechanisms and clinical expression, requesting treatments that will need to take into account all these specificities.

Deciphering this variability is one of the biggest challenges in the treatment of neurodegenerative diseases and the way forward is precision medicine, supported by highly personalised approaches for the greatest benefit of the patients.

In this context, in partnership with the European Commission, JPND has announced a new call, inviting multinational research teams to submit proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects to change the trajectory of these debilitating diseases through the development of precision medicine approaches.

Professor Philippe Amouyel, University of Lille and Chair of the JPND Management Board, said: “During the last ten years, researchers have progressively uncovered the high complexity and wide diversity of neurodegenerative diseases.

“We need now to complete and use this massive amount of knowledge to develop targeted approaches to more efficiently fight the dramatic progression of these diseases.”

Proposals submitted under this call, which is open to applicants in 24 countries, must focus on Precision Medicine in one or several of the following research areas: diagnosis; prevention and care.

Proposals must also relate to any or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor Neuron diseases, Hungtington’s disease, Spinocerebellar ataxia and Spinal muscular atrophy.